Neoantigen vaccine sparks powerful immune defense against kidney cancer
A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to long-lasting T cell expansion and no disease recurrence after 40 months.
Personalized vaccines halt kidney cancer after encouraging phase 1 trial
In a nutshell Researchers developed personalized cancer vaccines for nine high-risk kidney cancer patients, with all participants remaining cancer-free after nearly three years of follow-up – a significant advancement for a cancer type that traditionally has limited treatment options.
Cancer vaccine shows promise for patients with stage III and IV kidney cancer
Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.
New Vaccine Shows Promise For Kidney Cancer
A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer three years after the pioneering treatment.
Kidney Cancer Vaccine Shows Promise in Early Trial
In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated robust immune response, according to findings of a new study led by HMS researchers at Dana-Farber Cancer Institute.
Experimental vaccine seems to battle advanced kidney cancers
A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report.
Three Years After Experimental Vaccine, These Patients Are Still Cancer-Free
Scientists at the Dana-Farber Cancer Institute and elsewhere developed the vaccine, which is designed to prevent advanced cases of kidney cancer from returning. Since the trial patients received the vaccine roughly three years ago,
Personalized cancer vaccine shows potential in kidney cancer
In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.
labiotech1d
Needle-free vaccines: Micron Biomedical, Vaxxas, and IntegriMedical bring their new technologies to patients
Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...
Dog Owner Bringing Puppy in for Booster Shots Stunned by Vet's Accusation: 'Yuck'
The owner and original poster (OP), username LittleBucket07, who brought their 12-week-old Labrador for booster shots, took ...
Next-generation mRNA vaccine delivery system uses biodegradable polymers
A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.
Medscape6d
EMA Recommends Approval of Capvaxive Pneumococcal Vaccine
The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...
The American Journal of Managed Care1d
Promising Cancer Vaccine Boosts Hope for Stage III and IV Kidney Cancer
All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...